1.	A Phase 2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M05-780, NCT00297089
2.	A Study of ABT-751 in Patients With Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M02-446, NCT00073138
3.	A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M02-447, NCT00063102
4.	Phase II Study of ABT-751 in Patients With Locally Recurrent or Metastatic Renal Cell Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0308113, ABBOTT-M02-416, NCT00080717
5.	Phase II Study of ABT-751 in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Refractory to Taxane Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0308111, ABBOTT-M02-448, NCT00080730
6.	Phase II Study of ABT-751 in Children With Relapsed or Refractory Neuroblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Under 22 Sponsor: NCI Protocol IDs: COG-ANBL0621, ANBL0621, NCI-07-C-0074, NCI-P6554, NCT00436852
7.	ABT-751 in Treating Young Patients With Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and under Sponsor: NCI, NIH WGMCC Protocol IDs: 020141, 02-C-0141, ABBOTT-M01-357, CDR0000069344, NCI-02-C-0141, NCT00036959